Loading...
•
Jun 30, 2020
Iovance Q2 2020 Earnings Report
Reported second quarter 2020 financial results and provided a corporate update.
Key Takeaways
Iovance Biotherapeutics reported a net loss of $63.0 million for the second quarter of 2020, with research and development expenses at $49.3 million and general and administrative expenses at $14.4 million. The company held $777.4 million in cash, cash equivalents, short-term investments, and restricted cash as of June 30, 2020.
Completed dosing in pivotal melanoma program for lifileucel.
Announced data at AACR for Moffitt’s TIL in non-small cell lung cancer.
Presented updated Cohort 2 data for lifileucel at ASCO.
Completed enrollment in Cohort 1 of the C-145-04 cervical cancer study.
Forward Guidance
The company anticipates that the year-end balance of cash, cash equivalents, short-term investments and restricted cash may be over $630 million. The operating expenses in the second half of 2020 are forecasted to be in the same range as the first half of 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...